FivepHusion forms strategic collaboration with Treehill Partners and Syneos Health to bring novel, enhanced chemotherapeutic product to market

FivepHusion, an advanced clinical-stage biotechnology company, is collaborating with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health, a fully integrated biopharmaceutical solutions organization, to develop and bring a novel, enhanced chemotherapeutic product to market.

Treehill Partners will support FivepHusion with integrated business development, operational, strategic and transactional expertise. Syneos Health will support FivepHusion’s integrated clinical development and commercialization capabilities.

This collaboration is designed to strategically and optimally progress development and commercialization of FivepHusion’s enhanced chemotherapeutic formulation Deflexifol in global markets.

“This is a very exciting time for FivepHusion. We are at a crucial stage in our growth strategy. By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol to global markets, including in the US, Europe and Asia,” said Dr. Christian Toouli, CEO & Managing Director, FivepHusion.

“This collaboration represents a unique working model to the industry. Through the combined strength and competency of three industry leaders, we intend to maximize our progress on the development of Deflexifol and quickly bring innovative oncology medicines to patients in need.”

“We’re excited to collaborate with FivepHusion and Treehill Partners to help bring Deflexifol to patients,” said Christian Tucat, chief business officer, Syneos Health. “Leveraging our deep therapeutic and global expertise, Syneos Health is pleased to contribute to accelerating the clinical development and commercialization of this important new therapy.”

“This collaboration represents a new model of integrated services across disciplines, designed to allow US and non-US emerging players to play a key role on the global stage, and we’re proud to work alongside FivepHusion and Syneos Health,” said Ali Pashazadeh, partner & co-founder, Treehill Partners.

“By merging the scientific prowess of our clients with the clinical and commercial expertise of Syneos Health and Treehill’s healthcare advisory and execution capabilities, we are providing a unique ecosystem designed to help companies to flourish despite the current challenging market environment.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news